PepGen, Inc. (NASDAQ:PEPG) Given Consensus Rating of "Hold" by Analysts

Key Points

• PepGen, Inc. has received a consensus rating of "Hold" from six research firms, with two analysts rating it as a sell and four as a buy.
• The average 12-month price target for PepGen's stock is $8.40, with some analysts setting targets as high as $12.00.
• Major shareholder Science Enterprises Plc Oxford recently purchased 200,000 shares at an average price of $3.20, increasing their stake in the company significantly.

Shares of PepGen, Inc. (NASDAQ:PEPG - Get Free Report) have been given a consensus rating of "Hold" by the six research firms that are presently covering the stock, Marketbeat Ratings reports. Two equities research analysts have rated the stock with a sell rating and four have assigned a buy rating to the company. The average 12 month price target among brokerages that have updated their coverage on the stock in the last year is $8.40.

PEPG has been the subject of several recent analyst reports. Weiss Ratings reiterated a "sell (d-)" rating on shares of PepGen in a report on Wednesday, October 8th. Stifel Nicolaus raised their target price on shares of PepGen from $9.00 to $12.00 and gave the stock a "buy" rating in a report on Thursday, September 25th. HC Wainwright raised their target price on shares of PepGen from $8.00 to $12.00 and gave the stock a "buy" rating in a report on Thursday, September 25th. Guggenheim reiterated a "buy" rating and issued a $6.00 target price on shares of PepGen in a report on Wednesday, September 24th. Finally, Wedbush raised their target price on shares of PepGen from $7.00 to $9.00 and gave the stock an "outperform" rating in a report on Thursday, September 25th.

PepGen Trading Up 1.9%

NASDAQ:PEPG opened at $4.89 on Monday. PepGen has a twelve month low of $0.88 and a twelve month high of $9.15. The company has a 50-day moving average of $2.62 and a 200-day moving average of $1.81. The firm has a market cap of $160.39 million, a price-to-earnings ratio of -1.65 and a beta of 1.96.

PepGen (NASDAQ:PEPG - Get Free Report) last posted its quarterly earnings data on Thursday, August 7th. The company reported ($0.70) earnings per share for the quarter, beating the consensus estimate of ($0.85) by $0.15. On average, research analysts forecast that PepGen will post -2.73 earnings per share for the current year.

Insider Activity at PepGen

In related news, major shareholder Science Enterprises Plc Oxford purchased 200,000 shares of the firm's stock in a transaction that occurred on Tuesday, September 30th. The stock was acquired at an average cost of $3.20 per share, for a total transaction of $640,000.00. Following the completion of the acquisition, the insider owned 4,955,388 shares in the company, valued at $15,857,241.60. This trade represents a 4.21% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 4.60% of the company's stock.

Institutional Trading of PepGen

Institutional investors have recently made changes to their positions in the stock. XTX Topco Ltd acquired a new stake in shares of PepGen during the first quarter worth approximately $25,000. ADAR1 Capital Management LLC bought a new position in PepGen during the first quarter valued at approximately $29,000. Rangeley Capital LLC raised its position in PepGen by 133.3% during the second quarter. Rangeley Capital LLC now owns 35,000 shares of the company's stock valued at $39,000 after acquiring an additional 20,000 shares in the last quarter. Marshall Wace LLP bought a new position in PepGen during the second quarter valued at approximately $44,000. Finally, Qube Research & Technologies Ltd bought a new position in PepGen during the second quarter valued at approximately $81,000. 58.01% of the stock is currently owned by institutional investors and hedge funds.

About PepGen

PepGen Inc, a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. Its lead product candidate is PGN-EDO51, an EDO peptide that is in Phase 2 clinical trial to treat Duchenne muscular dystrophy (DMD) patients.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.